Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Synopsys, Inc. due to allegations of misleading statements and failure to disclose critical information regarding the company's financial performance and business operations [2][5]. Financial Performance - Synopsys reported third quarter 2025 revenue of $1.740 billion, which was below the prior guidance of $1.755 billion to $1.785 billion [6]. - The net income for the quarter was $242.5 million, representing a 43% decline from $425.9 million in the same quarter of 2024 [6]. - The Design IP segment accounted for approximately 25% of total revenue, generating $426.6 million, a 7.7% year-over-year decline [6]. - Management's guidance indicated that Design IP revenues are expected to decline by at least 5% for the full fiscal year 2025 [6]. Stock Market Reaction - Following the release of disappointing financial results, Synopsys's stock price fell by $216.59, or 35.8%, closing at $387.78 per share on September 10, 2025, with unusually high trading volume [7]. Legal Context - Investors who purchased securities in Synopsys between December 4, 2024, and September 9, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options, with a deadline of December 30, 2025, to seek the role of lead plaintiff in a federal securities class action [2][8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Firefly Aerospace Inc. due to allegations of misleading statements and operational issues that have negatively impacted the company's stock performance and investor confidence [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Firefly Aerospace to contact them regarding their legal options, particularly in light of a federal securities class action filed against the company [1][2]. - The deadline for investors to seek the role of lead plaintiff in the class action is January 12, 2026 [2]. Group 2: Financial Performance and Stock Impact - Firefly Aerospace conducted its IPO on August 7, 2025, selling 19.296 million shares at $45.00 per share [6]. - In its first earnings report as a public company on September 22, 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, in the same quarter of 2024 [7]. - Revenue for the second quarter of 2025 was $15.55 million, below analyst estimates of $17.25 million and down 26.2% year-over-year [7]. - The Spacecraft Solutions business segment reported revenue of only $9.2 million, representing a 49% year-over-year decrease [7]. - Following the earnings report, Firefly's stock price fell by $7.58 per share, or 15.31%, closing at $41.94 on September 23, 2025 [8]. - On September 29, 2025, Firefly disclosed a failure in the first stage of its Alpha Flight 7 rocket, leading to further concerns about the company's technology and commercial commitments [9][10]. - This news caused Firefly's stock price to drop by $7.66 per share, or 20.73%, closing at $29.30 on September 30, 2025 [10]. Group 3: Allegations Against Firefly - The complaint against Firefly alleges that the company overstated demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program [5]. - It is claimed that these misrepresentations would likely have a material negative impact on the company once revealed, affecting the integrity of the Offering Documents and public statements made during the class period [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [2][5][7]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal rights [1][2]. - There is a deadline of November 17, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [2]. Group 2: Misleading Statements - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission timeline and approval process for aficamten, expecting FDA approval in the second half of 2025 [5]. - The company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [5][6]. Group 3: Impact on Investors - Following the revelation of the misleading statements, class members purchased Cytokinetics' common stock at inflated prices and subsequently suffered significant losses [7]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Primo Brands Corporation due to alleged violations of federal securities laws related to misleading statements about the merger with BlueTriton Brands and its integration process [2][5]. Group 1: Allegations and Impact - The complaint alleges that Primo Brands and its executives made false and misleading statements regarding the merger, leading investors to believe it would enhance growth and operational efficiencies [5]. - Issues began to surface on August 7, 2025, when Primo Brands reported Q2 2025 earnings, revealing disruptions in product supply and service due to the merger [5]. - Following the August 7 disclosure, the stock price fell by $2.41, approximately 9%, from $26.41 to $24.00 [5]. Group 2: Further Developments - On November 6, 2025, Primo Brands significantly reduced its full-year 2025 net sales and adjusted EBITDA guidance, and announced the replacement of CEO Rietbroek [6]. - New CEO Eric Foss acknowledged that the company had moved "too far too fast" with integration efforts, resulting in various operational issues [6]. - After this announcement, the stock dropped by $8.20, or 36%, from $22.66 to $14.46 over the next two trading sessions [7]. Group 3: Legal Proceedings - Investors who suffered losses during the specified class period are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Primo Brands is January 12, 2026 [2]. - Any member of the putative class may move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug efzofitimod, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1]. - There is a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about efzofitimod, particularly regarding its ability to allow patients to taper steroid usage [5]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [6]. - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from $6.03 to $1.01 [6]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [7]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Call for Information - Faruqi & Faruqi encourages anyone with information regarding aTyr's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and undisclosed information regarding the company's prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Telix and its executives violated federal securities laws by making false statements and failing to disclose critical information about the company's progress and supply chain quality [5]. Group 2: Impact of Regulatory Actions - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [6]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [7]. Group 3: Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Any member of the class may move to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Stride, Inc. due to allegations of securities law violations, urging affected investors to contact them before the January 12, 2026 deadline for lead plaintiff applications in a federal class action lawsuit [2][5]. Group 1: Allegations Against Stride, Inc. - The complaint alleges that Stride and its executives made false or misleading statements and failed to disclose critical information regarding their products and services to educational institutions [5]. - Stride is accused of inflating enrollment numbers, cutting staff costs excessively, ignoring compliance requirements, and losing both existing and potential enrollments [5]. - A report indicated that the Gallup-McKinley County Schools Board of Education filed a complaint against Stride for fraud and deceptive practices, including retaining "ghost students" to secure state funding [6]. Group 2: Stock Price Impact - Following the allegations, Stride's stock price dropped by $18.60, or 11.7%, closing at $139.76 per share on September 15, 2025, negatively impacting investors [7]. - On October 28, 2025, Stride reported a deliberate limitation on enrollment growth and acknowledged "system implementation issues," leading to a significant drop in enrollments by approximately 10,000 to 15,000 [8]. - The stock price fell as much as 51% during intraday trading on October 29, 2025, further injuring investors [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Wildermuth Fund To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired in The Wildermuth Fund between November 1, 2020 and June 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - Nov ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's new Inspire V device and its market demand [2][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Inspire Medical to contact them directly to discuss their legal options [1]. - There is a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device, citing delays due to incomplete training and onboarding at treatment centers [6]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not effective until July 1, 2025, leading to continued use of the older Inspire IV system [6]. - Inspire reported weak demand and excess inventory for the Inspire V, resulting in a more than 80% cut in its 2025 earnings guidance [7]. Group 3: Market Impact - Following the announcement of these issues, Inspire Medical's stock price dropped over 32% in one day, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against KBR, Inc. related to alleged violations of federal securities laws, urging affected investors to contact them before the November 18, 2025 deadline for lead plaintiff applications in a federal securities class action [2][5]. Group 1: Allegations Against KBR - The complaint alleges that KBR and its executives made false and misleading statements regarding the Global Household Goods Contract with the U.S. Department of Defense's Transportation Command (TRANSCOM), despite being aware of material concerns about HomeSafe's ability to fulfill the contract [5]. - The lawsuit claims that KBR's statements about its business operations and prospects were materially false and misleading, leading to investor damages when the true information became public [5]. Group 2: Stock Price Impact - Following the announcement of TRANSCOM's notice to terminate the Global Household Goods Contract, KBR's stock price fell by $3.85 per share, or 7.29%, closing at $48.93 on June 20, 2025 [6]. - On the next trading day, KBR's stock experienced an additional decline of $1.30, or 2.65%, closing at $47.63 on June 23, 2025 [6]. Group 3: Legal Process and Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also adequate and typical of class members, overseeing the litigation on behalf of the class [7]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with their ability to share in any recovery unaffected by this decision [7].